Initial treatment with rosiglitazone/metformin fixed‐dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes

Aim:  This study assessed the efficacy and safety of rosiglitazone and metformin (RSG/MET) fixed‐dose combination (AVANDAMET) as initial therapy in patients with uncontrolled type 2 diabetes compared with monotherapy with either RSG or MET after 32 weeks of treatment.

[1]  S. Bowlin,et al.  Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. , 2004, Diabetes care.

[2]  Kingston H. Tseng,et al.  Standards of Medical Care in Diabetes–2006 , 2006, Diabetes Care.

[3]  H Keen,et al.  The Diabetes Control and Complications Trial (DCCT). , 1994, Health trends.

[4]  G. Charpentier.  Oral combination therapy for type 2 diabetes , 2002, Diabetes/metabolism research and reviews.

[5]  M. Abrahamson.  Clinical use of thiazolidinediones: recommendations. , 2003, The American journal of medicine.

[6]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[7]  M. Pladevall,et al.  Time to pharmacotherapy change in response to elevated HbA1c test results* , 2006, Current medical research and opinion.

[8]  Rury R. Holman,et al.  Glycemic Control with Diet, Sulfonylurea, Metformin, or Insulin in Patients with Type 2 Diabetes Mellitus: Progressive Requirement for Multiple Therapies (UKPDS 49) , 1999 .

[9]  J. Rosenstock,et al.  Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study , 2006, Diabetes, obesity & metabolism.

[10]  J. Hardman,et al.  Insulin, oral hypoglycemic agents and the pharmacology of the endocrine pancreas , 2001 .

[11]  S. Inzucchi,et al.  Oral Agents for Type 2 Diabetes: An Update , 2005 .

[12]  J. Rosenstock,et al.  Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study* , 2005, Current medical research and opinion.

[13]  R. Holman,et al.  Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. , 1999, JAMA.

[14]  A. Garber,et al.  Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. , 2003, The Journal of clinical endocrinology and metabolism.

[15]  Uk-Prospective-Diabetes-Study-Group.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[16]  C. Bailey,et al.  A Risk-Benefit Assessment of Metformin in Type 2 Diabetes Mellitus , 1999, Drug safety.

[17]  T. Funahashi,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Hypoadiponectinemia in Obesity and Type 2 Diabetes: Close Association with Insulin Resistance , 2022 .

[18]  S. Haffner,et al.  Effect of Rosiglitazone Treatment on Nontraditional Markers of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus , 2002, Circulation.

[19]  E. Horton,et al.  Troglitazone in Combination With Sulfonylurea Restores Glycemic Control in Patients With Type 2 Diabetes , 1998, Diabetes Care.

[20]  J. Rosenstock,et al.  Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. , 2000, JAMA.

[21]  G. Warsi,et al.  Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes , 2002, Diabetes/metabolism research and reviews.

[22]  Stephanie Thomas,et al.  Combination Medications in Diabetes Care: An Opportunity That Merits More Attention , 2003 .

[23]  Lee-Ming Chuang,et al.  Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. , 2002, Diabetes care.

[24]  Andrew Perry,et al.  Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis. , 2004, Clinical therapeutics.

[25]  D. Akbar.  Effect of metformin and sulfonylurea on C-reactive protein level in well-controlled type 2 diabetics with metabolic syndrome , 2003, Endocrine.

[26]  B. Zinman,et al.  Improving glucose management: Ten steps to get more patients with type 2 diabetes to glycaemic goal , 2005, International journal of clinical practice.

[27]  P. Scherer,et al.  Adiponectin: a relevant player in PPARγ-agonist-mediated improvements in hepatic insulin sensitivity? , 2005, International Journal of Obesity.

[28]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[29]  Y. Jang,et al.  Standards of Medical Care in Diabetes-2010 by the American Diabetes Association: Prevention and Management of Cardiovascular Disease , 2010 .

[30]  J. Levy,et al.  U.K. Prospective Diabetes Study 16: Overview of 6 Years' Therapy of Type II Diabetes: A Progressive Disease , 1995, Diabetes.

[31]  P. Raskin,et al.  Combination therapy for Type 2 diabetes: repaglinide plus rosiglitazone , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[32]  E. Araki,et al.  Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. , 1995, Diabetes research and clinical practice.

[33]  S. Inzucchi.  Oral antihyperglycemic therapy for type 2 diabetes: scientific review. , 2002, JAMA.